ACADIA Pharmaceuticals Inc (ACAD)
16.82
-0.25
(-1.46%)
USD |
NASDAQ |
Apr 19, 16:00
16.82
0.00 (0.00%)
After-Hours: 17:35
ACADIA Pharmaceuticals Research and Development Expense (Quarterly): 66.74M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 66.74M |
| September 30, 2023 | 156.96M |
| June 30, 2023 | 58.77M |
| March 31, 2023 | 69.14M |
| December 31, 2022 | 75.74M |
| September 30, 2022 | 81.34M |
| June 30, 2022 | 75.65M |
| March 31, 2022 | 128.86M |
| December 31, 2021 | 66.94M |
| September 30, 2021 | 58.56M |
| June 30, 2021 | 56.94M |
| March 31, 2021 | 56.97M |
| December 31, 2020 | 62.12M |
| September 30, 2020 | 120.08M |
| June 30, 2020 | 64.30M |
| March 31, 2020 | 72.64M |
| December 31, 2019 | 57.52M |
| September 30, 2019 | 62.62M |
| June 30, 2019 | 67.32M |
| March 31, 2019 | 52.92M |
| December 31, 2018 | 48.18M |
| September 30, 2018 | 53.11M |
| June 30, 2018 | 46.59M |
| March 31, 2018 | 39.28M |
| December 31, 2017 | 43.18M |
| Date | Value |
|---|---|
| September 30, 2017 | 36.42M |
| June 30, 2017 | 34.18M |
| March 31, 2017 | 35.41M |
| December 31, 2016 | 30.22M |
| September 30, 2016 | 25.81M |
| June 30, 2016 | 20.48M |
| March 31, 2016 | 22.78M |
| December 31, 2015 | 20.47M |
| September 30, 2015 | 18.73M |
| June 30, 2015 | 18.38M |
| March 31, 2015 | 16.30M |
| December 31, 2014 | 18.18M |
| September 30, 2014 | 16.95M |
| June 30, 2014 | 13.80M |
| March 31, 2014 | 11.67M |
| December 31, 2013 | 7.925M |
| September 30, 2013 | 7.254M |
| June 30, 2013 | 7.112M |
| March 31, 2013 | 4.43M |
| December 31, 2012 | 4.901M |
| September 30, 2012 | 4.40M |
| June 30, 2012 | 4.472M |
| March 31, 2012 | 5.021M |
| December 31, 2011 | 4.424M |
| September 30, 2011 | 4.158M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
56.94M
Minimum
Jun 2021
156.96M
Maximum
Sep 2023
76.80M
Average
66.94M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 17.12M |
| Amylyx Pharmaceuticals Inc | 44.91M |
| Regulus Therapeutics Inc | 5.763M |
| Minerva Neurosciences Inc | 4.721M |
| Viking Therapeutics Inc | 20.50M |